Spectral Medical Inc.
135 The West Mall, Unit 2
Toronto
Ontario
M9C 1C2
Canada
Tel: 416-626-3233 or 888-426-4264
Fax: 416-626-7383
Website: http://www.spectraldx.com/
Email: info@spectraldx.com
About Spectral Medical Inc.
Sepsis affects approximately 1,000,000 patients in the U.S. alone each year and millions worldwide. The ability to rapidly and accurately diagnose and treat this deadly disease remains one of the biggest challenges faced by healthcare professionals today. Using a unique and innovative theranostics approach, Spectral Medical is committed to decreasing the unacceptably high mortality rates caused by sepsis. By combining complementary diagnostics and therapeutics, or theranostics, Spectral’s vision is to provide products that will enable vastly improved outcomes of patients with severe sepsis.LEADERSHIP:
CEO: Paul Walker
CFO: Tony Businskas
PRODUCTS:
All Products
102 articles about Spectral Medical Inc.
-
Spectral Medical Announces Appointment of Leading Industry Executive Sam Amory as Dialco President
5/16/2022
Spectral Medical Inc. today announced the appointment of Samuel Amory as President of Dialco.
-
Spectral to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th
5/13/2022
Spectral Medical Inc. announced that Chris Seto, CEO and Dr. Jon Kellum, CMO of Spectral Medical, have been invited to present at the Spring Into Action - Best Ideas Investor Conference, which is being held virtually May 16th-20th, 2022.
-
Spectral Announces First Quarter 2022 Results and Provides Corporate Update
5/13/2022
Spectral Medical Inc. announced its financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Spectral Announces Fourth Quarter and Fiscal 2021 Results and Corporate Update
3/24/2022
Spectral Medical Inc. today announced its financial results for the fourth quarter and for the year ended December 31, 2021 and provided a corporate update.
-
Spectral Medical Announces Appointment of Blair McInnis as CFO
3/21/2022
Spectral Medical Inc. today announced the appointment of Blair McInnis as Chief Financial Officer, effective April 4, 2022.
-
Dialco Medical Announces Formation of Medical Advisory Board to Support the Continued Development of DIMI Device
3/16/2022
Spectral Medical Inc., announced that its wholly owned subsidiary, Dialco Medical Inc., has formed a Medical Advisory Board to support in guiding the DIMI usability trial and continued development of the DIMI device.
-
Spectral Medical CMO Dr. John Kellum to Present at the 27th International AKI & CRRT Conference on March 7-10, 2022
3/4/2022
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), announces that the Company’s Chief Medical Officer, Dr. John Kellum, has been selected to present at the 27th International Conference.
-
Spectral Medical Reports Progress on Tigris Clinical Trial
2/11/2022
Spectral Medical Inc. provided a clinical trial update on Tigris, a follow on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.
-
Spectral Medical Announces U.S. FDA Approval of DIMI Trial Protocol AmendmentAmendment expected to overcome key pandemic challenges and improve both site and patient enrollment
1/31/2022
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”) has received approval of a protocol amendment to its DIMI usability trial from the United States Federal Food and Drug Agency (“FDA”).
-
Sigyn is not only trying to treat the inflammatory mediators that fuel sepsis; it wants to prevent the life-threatening event from occurring altogether.
-
Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021
12/3/2021
Spectral Medical Inc. today announced that Chris Seto, Chief Executive Officer of Spectral Medical, is scheduled to present at the SNN Network Canada Virtual Event taking place on December 7-9, 2021.
-
Spectral Medical Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments
11/30/2021
Spectral Medical Inc. and its wholly-owned subsidiary Dialco Medical Inc., announced that it will host a conference call at 2:00 PM EST on Thursday, December 2, 2021, to provide a clinical update and discuss the latest business developments.
-
Spectral Medical Announces U.S. FDA Approval of Tigris Trial Protocol Amendment to Expand Inclusion Criteria
11/29/2021
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that the United States Federal Food and Drug Agency (“FDA”) has approved a protocol amendment to its Tigris trial allowing for the use of sequential organ failure assessment (“SOFA”) scoring as inclusion criteria into the study.
-
Spectral Announces Third Quarter 2021 Results and Provides Corporate Update
11/12/2021
Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc., announced its financial results for the third quarter ended September 30, 2021, and provided a corporate update.
-
Spectral to Present at the Benzinga Global Small Cap Conference on October 27, 2021
10/25/2021
Spectral Medical Inc. today announced that Chris Seto, Chief Executive Officer of Spectral, will present at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021.
-
Spectral Medical’s CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day and Sepsis Awareness Month
9/13/2021
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that Dr. John Kellum, Spectral’s Chief Medical Officer, has been recognized as a World Expert in Sepsis by Expertscape.
-
Spectral Medical Announces its Participation at Upcoming Investor Conferences
8/23/2021
Spectral Medical Inc. today announced its management will participate in the following virtual Investor Conferences: HC Wainwright 23rd Annual Global Investment, September 13-15, 2021.
-
Spectral Announces Second Quarter Results and Provides Corporate Update
8/13/2021
Spectral Medical Inc. today announced its financial results for the second quarter ended June 30, 2021, and provided a corporate update.
-
Spectral Medical Inc. Provides Tigris Clinical Trial Update
7/28/2021
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today provided a clinical trial update on Tigris, a follow on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
-
Dialco Medical Inc. Engages CROMSOURCE as Contract Research Organization Partner for DIMI IDE Trial
6/7/2021
Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Dialco has engaged CROMSOURCE, a full-service Contract Research Organization (“CRO”), for its upcoming DIMI IDE usability clinical trial.